[email protected]
CDI - Contrive Datum Insights
Healthcare Services

Home Infusion Therapy MarketSize, Share & Industry Analysis, 2026-2034By Therapy TypeBy ProductBy Service TypeBy Route of AdministrationBy IndicationBy Provider TypeBy Patient Age GroupBy Payer TypeBy Care SettingBy Duration of Therapy

Full title & scope — all 10 axes with their segments

Home Infusion Therapy Market Size, Share & Industry Analysis, By Therapy Type (Anti-Infective Therapy, Parenteral Nutrition, Enteral Nutrition, Immunoglobulin Therapy, Chemotherapy, Pain Management, Hydration Therapy, Inotropic and Cardiac Therapy, Specialty Biologics and Rare Disease Therapies), By Product (Infusion Pumps, IV Sets and Administration Sets, IV Catheters and Access Devices, IV Bags and Containers, Needleless Connectors and Accessories), By Service Type (Pharmacy Compounding and Dispensing, Skilled Nursing and Clinical Services, Equipment Rental and Supply, Patient Training and Care Coordination, Remote Patient Monitoring and Telepharmacy), By Route of Administration (Intravenous, Subcutaneous, Enteral, Epidural and Intrathecal, Intramuscular), By Indication (Infectious Diseases, Cancer, Primary and Secondary Immunodeficiency, Gastrointestinal Disorders and Short Bowel Syndrome, Neurological and Autoimmune Disorders, Hemophilia and Bleeding Disorders, Cardiovascular Disorders, Diabetes, Chronic Pain), By Provider Type (Independent Home Infusion Pharmacies, Hospital-Based Infusion Providers, Payer-Owned Infusion Providers, Specialty Pharmacy-Affiliated Providers, Home Health Agency-Based Providers), By Patient Age Group (Pediatric, Adult, Geriatric), By Payer Type (Medicare, Medicaid and Government Programs, Commercial Insurance, Out-of-Pocket and Self-Pay), By Care Setting (Patient Home, Ambulatory Infusion Suites, Assisted Living Facilities, Skilled Nursing Facilities), By Duration of Therapy (Short-Term (Acute) Therapy, Long-Term (Chronic) Therapy, Intermittent and Episodic Therapy), and Regional Forecast, 2026-2034

Last Updated: Nov 18, 2026Format: PDFReport ID: CDI-248901
Methodology

How the estimates were built: data sources, modelling approach and validation steps.

Research approach

A market size is a claim about the world, and a claim is only as good as the route to it. Every study is built upward from units and prices — what is actually produced, sold or performed, at what it actually changes hands for — rather than from a headline figure divided downwards. Disclosed company revenue is then used to check that build, not to produce it.

Market size estimation, this report

The market was built upward from the number of patients receiving infusion therapy at home each year, the average treatment days per patient and the realised per diem payment for drug, nursing, supplies and equipment. Volumes were set by therapy, then by care setting, using claims-based utilisation patterns and provider filings. Realised prices were taken from Medicare home infusion payment categories and commercial per diem contracts reported by providers. The resulting total was then checked against disclosed revenue of the listed home infusion providers and device suppliers. Where the build and the disclosed revenue disagreed, the bottom-up assumptions on patient volumes or per diem rates were corrected; the disclosed revenue was not averaged in.

The four stages

The same sequence runs behind every published study, whatever the industry. The order matters as much as the steps: the segment axes are fixed before any number is collected, so the model is never reshaped to fit whatever data happens to turn up.

1
Scope and segmentation
2
Bottom-up sizing
3
Reconciliation
4
Forecast

What the build rests on, and what checks it

The two are not interchangeable. The left column produces the number; the right column tests it. When the check disagrees with the build, the answer is to find which bottom-up assumption is wrong — a unit count, a price, a take-up rate — not to split the difference between them.

The bottom-up build rests on
  • Volume actually transacted — units produced, installed, dispensed or procedures performed, counted at the level each is genuinely recorded
  • Realised pricing by tier and channel, rather than one blended average applied across the whole market
  • Take-up and frequency: how much of the addressable base buys, and how often it repeats
The build is checked against
  • Disclosed revenue of the companies serving the market, where filings separate it far enough to be usable
  • Buyer-side spending totals — capital budgets, procurement lines, or the output of the end market the product is bought against
  • Trade and customs flows, where the product crosses borders in a separately recorded form
Bottom-up sequence
1
Size the base
2
Apply take-up
3
Apply frequency
4
Apply realised price
Reconciliation sequence
1
Gather disclosed revenue
2
Strip out-of-scope lines
3
Compare against the build
4
Correct the assumption

Data sources

Published data establishes what happened. Only the people transacting in a market can say why, and what is about to change — so the two are collected separately and weighted differently.

Primary — who is interviewed
  • Commercial and product leadership at the companies that supply the market
  • Procurement and specification leads at the organisations that buy it
  • Distributors, integrators and channel partners, where the market is served indirectly
  • Regulatory and standards specialists, where approval governs what can be sold at all
Secondary — what is read
  • Company filings, annual reports and investor disclosure
  • Government statistics, customs records and regulatory registers
  • Trade association output and standards-body publications
  • Technical and peer-reviewed literature, where the market rests on a clinical or engineering claim
Primary research design, this report

Interviews target infusion pharmacy owners and operations heads, directors of nursing, payer pharmacy and medical policy managers, hospital discharge and case management leaders, specialty pharmacy buyers and procurement managers at device suppliers. Regulatory affairs contacts who handle state pharmacy board licensing and accreditation are included because compounding rules shape what providers can offer. Sampling emphasises the United States, which carries most spending, with a second weight on Western Europe and Japan, where home infusion programmes are expanding. Smaller coverage in China, India, Brazil and the Gulf states is used to test adoption timing and reimbursement structure in markets where reporting is thin.

Secondary sources, this report

Desk research rests on the Medicare home infusion therapy services benefit and its HCPCS payment categories, the CMS durable medical equipment fee schedule, and FDA drug and device registers, including the 510(k) clearance database and compounding facility registrations. Utilisation was cross-checked against state pharmacy board licence counts and the benchmarks published by the National Home Infusion Association. Company annual reports, 10-K filings and investor presentations for listed providers and device makers supply disclosed revenue by segment. Customs data under HS code 9018 supports infusion set and pump trade flows.

Desk research runs across proprietary research databases including Factiva, OneSource and Hoovers alongside the public sources above. Modelling and statistical validation are run in SAS and SPSS.

Forecasting

The forecast is not a growth rate applied to a base year. It is built from the drivers that are expected to change, each one stated so a reader can disagree with it.

Forecast approach, this report

The forecast extends patient volumes and per diem payments by therapy and by care setting. Growth rests on continued transfer of infusion from hospital outpatient departments to the home, expansion of specialty biologic and immunoglobulin use, an ageing patient base, and gradual widening of coverage for home infusion drugs. Pricing is held broadly flat in real terms, with biologic mix lifting the average. A normalisation was applied to the period after 2020, when elective care was deferred. For the forecast to hold, payer policy must keep favouring lower cost settings, nursing capacity must keep pace with referrals, and supply of core infusion fluids must stay stable.

Triangulation and validation

No figure enters a report on the strength of one source. Where the two sizing routes disagree the difference is not averaged away — the assumption causing it is isolated, tested against a third independent measure, and either corrected or carried forward as a stated limitation. Historical years are back-tested against the growth actually recorded before any forecast is allowed to run forward from them.

Validation, this report

Outputs were back-tested against recorded growth in provider revenue and Medicare home infusion claims for 2020 to 2024, and the 2025 base was compared with the revenue disclosed by listed providers and device makers. Segment shifts, such as the rise of specialty biologics and subcutaneous administration, were reviewed with industry experts for direction and pace. Sensitivities covered patient volume, per diem rate, biologic mix and the speed of site-of-care transfer, each varied separately to see which assumption moved the 2034 total most. Regional splits were tested for consistency with national health spending patterns.

Confidence and limitations

Where an estimate is firm and where it is not is stated rather than left to be inferred from the precision of the number.

Confidence framing, this report

The estimate is firmest in the United States, where reimbursement categories, provider filings and device registers allow volumes and prices to be traced for anti-infective, parenteral nutrition and immunoglobulin therapy. It is weaker for specialty biologics delivered at home, for Asia Pacific, Latin America and the Middle East and Africa, where reporting is thin and coverage rules differ, and for assisted living and ambulatory suite settings. Changes to Medicare home infusion payment rules, drug supply disruptions or faster subcutaneous conversion would force a revision. A range of plus or minus ten percent around the base year total is a fair reading.

Scope

Questions This Report Answers

6 questions
01

What is the market size and growth rate, globally and by region?

02

How is the market segmented, and which segments lead?

03

Which regions and countries are covered, and how do they compare?

04

What are the key drivers, restraints, opportunities and challenges?

05

Who are the leading companies operating in this market?

06

What trends are expected to shape the market through the forecast period?

Questions

Frequently Asked Questions

01What is the Home Infusion Therapy Market projected to reach?

USD 82.96 USD Billion by 2034, CAGR 8%

02What years does this report cover?

Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.

03Which regions are covered?

North America, Europe, Asia Pacific, Latin America, Middle East and Africa.

04Which segment leads the market?

Anti-Infective Therapy is the largest line by therapy type, at 26.99% of revenue in 2025.

05Who are the key companies profiled?

Option Care Health, Inc., Optum Infusion Pharmacy (UnitedHealth Group Incorporated), Coram (CVS Health Corporation), BrightSpring Health Services, Inc., Amerita, Inc., KabaFusion, Baxter International Inc., B. Braun Melsungen AG, BD (Becton, Dickinson and Company), ICU Medical, Inc., Fresenius Kabi AG, Soleo Health, Triple Crown Infusion Services, Vivo Infusion, Premier Infusion Care, Wellsky Corporation (CareCentrix), Avant Healthcare Professionals, ARJ Infusion Services, Eversana Life Science Services LLC, Smiths Medical (ICU Medical), Moog Medical Devices Group, Terumo Corporation, Nipro Corporation, Zyno Medical, InfuSystem Holdings, Inc., Sanofi (Home infusion support), Takeda Pharmaceutical Company Limited, CSL Behring (CSL Limited), Fresenius Kabi Home Care, Medline Industries, LP, Apria Healthcare Group, Lincare Holdings Inc., Linde Healthcare Homecare, Vitalaire (Air Liquide Santé), Orkla Care. Full profiles are part of the paid report.

06Can the segmentation be customized?

Yes. Custom data cuts by geography, segment, or competitor set are available on request.

425+
Dedicated research analysts
1,200+
Reports published
Why CDI

Why choose CDI

Data triangulated across primary and secondary sources
Complimentary analyst call included with every purchase
Custom data cuts and post-purchase support available

Need this report shaped around your question?

The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.

Most licences include 30–60 hours of customization at no extra cost. See what each licence includes

Request customization

Additional Companies

Add competitors, suppliers or the peer set you benchmark against to the companies already covered.

Deeper Competitive View

Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.

Extra Segment Splits

Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.

Application Focus

Narrow the analysis to the specific use cases and end users your team actually sells into.

Different Time Frame

Move the base year, or widen the historical and forecast windows the study is built on.

Country-Level Detail

Go below region level into the individual countries that matter to you, rather than the standard geography split.